Despite decades of progress in pediatric oncology, outcomes for children with high-risk or recurrent rhabdomyosarcoma (RMS) remain discouragingly low. While some patients with intermediate-risk ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results